Skip to main
MDGL
MDGL logo

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals (MDGL) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Madrigal Pharmaceuticals Inc. has reported robust growth for its medication, Rezdiffra, evidenced by a significant 44% quarter-over-quarter increase in the number of patients using the drug, resulting in a 33% quarter-over-quarter rise in net sales. Upcoming data from the Phase 2 MAESTRO-NAFLD study on compensated MASH cirrhosis is poised to enhance the prospects of the ongoing MAESTRO-Outcomes trial, thereby bolstering the validity of Rezdiffra in treating this serious condition. Furthermore, potential expansion into later-stage F4c could further widen the patient population, with supportive data anticipated from the Phase 3 MAESTRO-NAFLD-1 trial, signaling strong future growth opportunities for the company.

Bears say

Madrigal Pharmaceuticals faces a negative outlook primarily due to potential negative safety and efficacy results from late-stage clinical trials, which could lead to significant downward revisions in financial projections. Additionally, the company may encounter market access and reimbursement challenges that could hinder initial adoption of its product Rezdiffra, similar to issues experienced by other recent launches in related therapeutic areas. Furthermore, increasing competition in the field of metabolic dysfunction-associated steatohepatitis (MASH) could create long-term barriers to achieving a substantial market share for Madrigal's therapeutics.

Madrigal Pharmaceuticals (MDGL) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Madrigal Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Madrigal Pharmaceuticals (MDGL) Forecast

Analysts have given Madrigal Pharmaceuticals (MDGL) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Madrigal Pharmaceuticals (MDGL) has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $532.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $532.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Madrigal Pharmaceuticals (MDGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.